register

News & Trends - Pharmaceuticals

GSK partners with digital health company to advance remote patient monitoring

Health Industry Hub | July 29, 2022 |
[Total: 2    Average: 4.5/5]

Pharma News: The digital respiratory devices market may hit $405 million in value by 2030, growing globally at a 27.31% CAGR from 2021. Increasing prevalence of respiratory diseases, increasing adoption of digital technology among individuals and treatment satisfaction with inhaled therapy are fuelling the growth of the market.

Australia’s Adherium, a leader in respiratory ehealth, has received Food and Drug Administration (FDA) clearance to market an application connecting GlaxoSmithKline’s (GSK) Ellipta inhaler users with Adherium’s next generation Hailie sensor with physiological parameters for monitoring asthma and chronic obstructive pulmonary disease (COPD) medication use.

Following market clearance of the Hailie sensor with physiological parameters for AstraZeneca’s Symbicort MDI inhaler last September, Adherium’s latest Hailie sensor is designed for use with the GSK’s Breo, Anoro, Incruse, Trelegy and Arnuity Ellipta dry powder inhalers (DPIs) and captures physiological parameters, including inhalation duration, volume, and peak inhalation flow. This new series of devices provide a superior perspective into inhaler usage and technique giving patients and doctors immediate, real-time feedback thereby allowing patients to improve their quality of life and enabling physicians to enhance patient care by capturing clinical data supporting patient management and treatment.

Rick Legleiter, Adherium CEO, commented “Executing our strategy and once again delivering on our product roadmap milestones, we continue to demonstrate Adherium is the global partner of choice for remote patient monitoring.

“The clearance to connect Ellipta inhaler users with our new, next generation Hallie platform represents another major step forward in our drug agnostic strategy. In addition, this further broadens the pathway for doctors and hospital groups in the US to access reimbursement for remote monitoring of patients prescribed Asthma and COPD medications on our path toward building a sustainable, cash flow positive business.”

Tara Creaven-Capasso, Adherium’s Vice President Quality, Regulatory and Clinical Affairs, said “We enhance healthcare outcomes by improving quality of life for patients around the world and reduce emergency department visits and hospital admissions and the economic burden of chronic respiratory diseases.”

Adherium continues its global expansion strategy to extend its digital technological innovations to enable reimbursement on 18 of the top 20 US branded inhaler medications in 2023.


Human Resources

New gender pay gap data highlights disproportionate impact of inflation on Australian women

Health Industry Hub | August 19, 2022 |

Human Resources: Men are earning an average of $263.90 more than women a week, according to the latest gender pay gap data. […]

More


News & Trends - Medical Technology

MedTech News -

MedTech partnership to support brain and spine therapy in Asia Pacific region

Health Industry Hub | August 19, 2022 |

MedTech News: A new medtech partnership will support specialist physicians from across the Asia-Pacific region and pioneer new precision approaches […]

More


News & Trends - Pharmaceuticals

Consumer Health Forum and Patient Voice Initiative join Medicines Australia in voicing priorities for NMP Review restart

Health Industry Hub | August 19, 2022 |

Pharma News: Medicines Australia welcomes the restart of the National Medicines Policy (NMP) Review, which was put on hold prior […]

More


News & Trends - Pharmaceuticals

First public hospital to launch e-prescriptions in changing the dynamics of how patients access medicines

Health Industry Hub | August 19, 2022 |

Pharma News: In a first for public hospitals nationally, patients at Royal Perth Hospital can now obtain electronic prescriptions that […]

More


This content is copyright protected